BriaCell rises as co begins enrollment for breast cancer treatment trial
14/07/2021 13:01
** U.S.-listed shares of drug developer BCTX.O up 3.1% at
$6 premarket
** Co announces open recruitment and enrollment for
early-to-mid stage study to test its lead candidate, Bria-IMT,
along with Incyte's INCY.O treatments in patients with
advanced breast cancer
** BriaCell and Incyte's program is a non-exclusive
collaboration to evaluate effects of combinations of novel
clinical candidates
** Under the agreement, Incyte is providing compounds from
its development portfolio including retifanlimab and epacadostat
urn:newsml:reuters.com:*:nGNX5dSNbj
** Up to Tuesday's close, stock rose 40.3% YTD
(Reporting by Dania Nadeem in Bengaluru)
((Dania.Nadeem@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study